Latest News
August 13, 2018
Clinical Benefits of TPX-100 in Knee Osteoarthritis Patients are Associated with Improvements in Knee Cartilage Structure Modification
April 17, 2018
OrthoTrophix Will Present Data on Long-Term Clinical Benefit of TPX-100 in Mild to Severe Knee Osteoarthritis Patients at OARSI Annual Meeting 2018
November 7, 2017
OrthoTrophix Presents the Key Data of the TPX-100 Phase 2 Study as a Late Breaking Abstract at American College of Rheumatology Annual Meeting
Welcome
OrthoTrophix is an emerging biopharmaceutical company focused on the development and commercialization of revolutionary therapies for the treatment of diseases and conditions involving hard tissues such as bone, cartilage and teeth. The primary focus of OrthoTrophix is regeneration and repair of cartilage in the knee and other joints. The company‘s leading therapeutic compound, TPX-100, has demonstrated a sound safety profile as well as statistically significant and clinically meaningful improvements in function and other parameters of the knees in knee osteoarthritis subjects in a Phase 2 clinical study. In addition, a significant improvement in cartilage structure was also observed. Prior to initiation of clinical studies, TPX-100 had demonstrated ability to repair articular (hyaline) cartilage in experimental defects in the knee joints of ambulatory large animal models.
